This emulated target trial provides robust clinical evidence that prucalopride is associated with a lower risk of depression in those with no previous diagnosis, compared with alternative anti-constipation agents, supporting the hypothesis that 5-HT4R agonists have antidepressant properties. This evidence concerns the gene HTR4 and major depressive disorder.